Consensus 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
25.7 ^USD	+0.23%		-2.58%	+26.85%

May. 09	4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT

Evolution of the average Target Price on 4D Molecular Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

cb4.QpGGYmZ8x8hQtYoUovnFfran53rP94QxDZzCs3IGuY4.M6ftOi0NsZIX_utt9InxK4H3nheFqMAGVaqb2CNp3PgV0PANCAuPrgP55Q~c2260d66ae0fab1551a3af72ed6bdc6f

Analyst Recommendations on 4D Molecular Therapeutics, Inc.

Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	Apr. 15	MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 15	MT
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	Apr. 04	MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating	Apr. 01	MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating	Apr. 01	MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating	Feb. 05	MT
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	Feb. 05	MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk	Feb. 05	MT
Chardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy Rating	23-07-11	MT
Chardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price Target	23-07-05	MT
BofA Adjusts Price Target on 4D Molecular Therapeutics to $33 From $28, Keeps Buy Rating	23-06-08	MT
SVB Securities Trims Price Target on 4D Molecular Therapeutics to $13 From $14, Keeps Market Perform Rating	23-04-13	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $14 From $15, Maintains Market Perform Rating	23-02-06	MT
BMO Capital Starts 4D Molecular Therapeutics at Outperform With $50 Price Target	23-01-30	MT
HC Wainwright Starts 4D Molecular Therapeutics at Buy With $36 Price Target	22-11-18	MT
Goldman Sachs Upgrades 4D Molecular Therapeutics to Buy From Neutral, Raises Price Target to $68 From $12	22-11-15	MT
SVB Securities Raises 4D Molecular Therapeutics' Price Target to $15 From $11, Keeps Market Perform Rating	22-11-14	MT
Evercore ISI Adjusts 4D Molecular Therapeutics Price Target to $45 From $32, Maintains Outperform Rating	22-11-14	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $11 From $10, Maintains Market Perform Rating	22-11-10	MT
SVB Securities Downgrades 4D Molecular Therapeutics to Market Perform From Outperform Rating, Adjusts Price Target to $12 From $28	22-08-12	MT
Jefferies Starts 4D Molecular Therapeutics at Buy With $22 Price Target	22-06-22	MT
SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating	22-05-13	MT
SVB Leerink Starts 4D Molecular Therapeutics at Outperform With $30 Price Target	22-01-04	MT
4D MOLECULAR THERAPEUTICS : BofA Securities Starts 4D Molecular Therapeutics at Buy With $47 Price Target	21-01-05	MT
4D MOLECULAR THERAPEUTICS : Evercore ISI Starts 4D Molecular Therapeutics at Outperform With $70 Price Target	21-01-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.7 USD

Average target price

52.3 USD

Spread / Average Target

+103.50%

High Price Target

82 USD

Spread / Highest target

+219.07%

Low Price Target

35 USD

Spread / Lowest Target

+36.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering 4D Molecular Therapeutics, Inc.

Barclays
RBC Capital Markets
BMO Capital
Jefferies & Co.
Chardan Research
BofA Securities
SVB Securities LLC
HC Wainwright
Goldman Sachs
Evercore ISI
SVB Leerink

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar